Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: An open pilot studyCitation formats

  • Authors:
  • J. J. Egan
  • H. I. Adamali
  • S. S. Lok
  • J. P. Stewart
  • A. A. Woodcock

Standard

Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: An open pilot study. / Egan, J. J.; Adamali, H. I.; Lok, S. S.; Stewart, J. P.; Woodcock, A. A.

In: Pulmonary Medicine, 2011.

Research output: Contribution to journalArticle

Harvard

Egan, JJ, Adamali, HI, Lok, SS, Stewart, JP & Woodcock, AA 2011, 'Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: An open pilot study' Pulmonary Medicine. https://doi.org/10.1155/2011/240805

APA

Egan, J. J., Adamali, H. I., Lok, S. S., Stewart, J. P., & Woodcock, A. A. (2011). Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: An open pilot study. Pulmonary Medicine, [240805]. https://doi.org/10.1155/2011/240805

Vancouver

Egan JJ, Adamali HI, Lok SS, Stewart JP, Woodcock AA. Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: An open pilot study. Pulmonary Medicine. 2011. 240805. https://doi.org/10.1155/2011/240805

Author

Egan, J. J. ; Adamali, H. I. ; Lok, S. S. ; Stewart, J. P. ; Woodcock, A. A. / Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: An open pilot study. In: Pulmonary Medicine. 2011.

Bibtex

@article{3079985e52fb4e45810ee0d56cf386c4,
title = "Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: An open pilot study",
abstract = "Hypothesis. Repeated epithelial cell injury secondary to viruses such as Epstein Barr and subsequent dysfunctional repair may be central to the pathogenesis of IPF. In this observational study, we evaluated whether a combination of standard and anti-viral therapy might have an impact on disease progression. Methods. Advanced IPF patients who failed standard therapy and had serological evidence of previous EBV, received ganciclovir (iv) at 5mg/kg twice daily. Forced vital capacity (FVC), shuttle walk test, DTPA scan and prednisolone dose were measured before and 8 weeks post-treatment. Results. Fourteen patients were included. After ganciclovir, eight patients showed improvement in FVC and six deteriorated. The median reduction of prednisolone dose was 7.5mg (44{\%}). Nine patients were classified {"}responders{"} of whom four showed an improvement in all four criteria, while three of the five non-responders showed no response in any of the criteria. Responders showed reduction in prednisolone dosage (P=.02) and improved DTPA clearance (P=.001). Conclusion. This audit outcome suggests that 2-week course of ganciclovir (iv) may attenuate disease progression in a subgroup of advanced IPF patients. These observations do not suggest that anti-viral treatment is a substitute for the standard care, however, suggests the need to explore the efficacy of ganciclovir as adjunctive therapy in IPF. {\circledC} 2011 J. J. Egan et al.",
author = "Egan, {J. J.} and Adamali, {H. I.} and Lok, {S. S.} and Stewart, {J. P.} and Woodcock, {A. A.}",
year = "2011",
doi = "10.1155/2011/240805",
language = "English",
journal = "Pulmonary Medicine",
issn = "2090-1836",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: An open pilot study

AU - Egan, J. J.

AU - Adamali, H. I.

AU - Lok, S. S.

AU - Stewart, J. P.

AU - Woodcock, A. A.

PY - 2011

Y1 - 2011

N2 - Hypothesis. Repeated epithelial cell injury secondary to viruses such as Epstein Barr and subsequent dysfunctional repair may be central to the pathogenesis of IPF. In this observational study, we evaluated whether a combination of standard and anti-viral therapy might have an impact on disease progression. Methods. Advanced IPF patients who failed standard therapy and had serological evidence of previous EBV, received ganciclovir (iv) at 5mg/kg twice daily. Forced vital capacity (FVC), shuttle walk test, DTPA scan and prednisolone dose were measured before and 8 weeks post-treatment. Results. Fourteen patients were included. After ganciclovir, eight patients showed improvement in FVC and six deteriorated. The median reduction of prednisolone dose was 7.5mg (44%). Nine patients were classified "responders" of whom four showed an improvement in all four criteria, while three of the five non-responders showed no response in any of the criteria. Responders showed reduction in prednisolone dosage (P=.02) and improved DTPA clearance (P=.001). Conclusion. This audit outcome suggests that 2-week course of ganciclovir (iv) may attenuate disease progression in a subgroup of advanced IPF patients. These observations do not suggest that anti-viral treatment is a substitute for the standard care, however, suggests the need to explore the efficacy of ganciclovir as adjunctive therapy in IPF. © 2011 J. J. Egan et al.

AB - Hypothesis. Repeated epithelial cell injury secondary to viruses such as Epstein Barr and subsequent dysfunctional repair may be central to the pathogenesis of IPF. In this observational study, we evaluated whether a combination of standard and anti-viral therapy might have an impact on disease progression. Methods. Advanced IPF patients who failed standard therapy and had serological evidence of previous EBV, received ganciclovir (iv) at 5mg/kg twice daily. Forced vital capacity (FVC), shuttle walk test, DTPA scan and prednisolone dose were measured before and 8 weeks post-treatment. Results. Fourteen patients were included. After ganciclovir, eight patients showed improvement in FVC and six deteriorated. The median reduction of prednisolone dose was 7.5mg (44%). Nine patients were classified "responders" of whom four showed an improvement in all four criteria, while three of the five non-responders showed no response in any of the criteria. Responders showed reduction in prednisolone dosage (P=.02) and improved DTPA clearance (P=.001). Conclusion. This audit outcome suggests that 2-week course of ganciclovir (iv) may attenuate disease progression in a subgroup of advanced IPF patients. These observations do not suggest that anti-viral treatment is a substitute for the standard care, however, suggests the need to explore the efficacy of ganciclovir as adjunctive therapy in IPF. © 2011 J. J. Egan et al.

U2 - 10.1155/2011/240805

DO - 10.1155/2011/240805

M3 - Article

JO - Pulmonary Medicine

JF - Pulmonary Medicine

SN - 2090-1836

M1 - 240805

ER -